Norio Akuta Selected Research

Chronic Hepatitis B

10/2023	Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance.
2/2022	Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B.
1/2022	Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
11/2021	Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs.
4/2021	Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
4/2021	Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
2/2019	Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
1/2019	Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
5/2017	Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
12/2015	Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Norio Akuta Research Topics

Disease

92	Hepatocellular Carcinoma (Hepatoma) 10/2023 - 01/2002
56	Infections 10/2019 - 01/2002
52	Chronic Hepatitis C 12/2020 - 01/2002
51	Chronic Hepatitis B 10/2023 - 01/2002
46	Fibrosis (Cirrhosis) 12/2023 - 01/2002
28	Liver Cirrhosis (Hepatic Cirrhosis) 02/2020 - 01/2002
26	Neoplasms (Cancer) 01/2023 - 01/2003
26	Hepatitis 01/2014 - 01/2002
20	Liver Diseases (Liver Disease) 10/2022 - 01/2002
17	Chronic Hepatitis (Chronic Active Hepatitis) 03/2014 - 01/2003
16	Non-alcoholic Fatty Liver Disease 07/2023 - 01/2011
15	Hepatitis B 01/2022 - 01/2002
11	Carcinogenesis 01/2014 - 01/2003
10	Type 2 Diabetes Mellitus (MODY) 01/2022 - 03/2009
10	Hepatitis C 11/2015 - 09/2005
9	Liver Neoplasms (Liver Cancer) 07/2023 - 12/2010
9	Diabetes Mellitus 07/2023 - 11/2008
9	Anemia 10/2014 - 07/2004
5	Disease Progression 09/2023 - 01/2004
5	Viremia 01/2017 - 01/2007
4	Insulin Resistance 01/2022 - 06/2009
4	Virus Diseases (Viral Diseases) 04/2021 - 01/2004
4	Body Weight (Weight, Body) 01/2018 - 10/2007
4	Hypertension (High Blood Pressure) 03/2014 - 09/2009
4	Persistent Infection 10/2013 - 05/2005
3	Fatty Liver 04/2022 - 09/2009
3	Lymphoma (Lymphomas) 12/2019 - 04/2003
3	Hepatic Encephalopathy 12/2019 - 10/2004
3	Thrombocytopenia (Thrombopenia) 10/2017 - 05/2009
3	Liver Failure 09/2012 - 01/2004
2	Proteinuria 09/2023 - 10/2022
2	Autoimmune Hepatitis 10/2022 - 07/2010
2	Fever (Fevers) 10/2022 - 03/2012

Drug/Important Bio-Agent (IBA)

73	InterferonsIBA 12/2020 - 01/2002
38	Ribavirin (Virazole)FDA LinkGeneric 01/2018 - 01/2002
35	Lamivudine (Epivir)FDA Link 05/2017 - 01/2002
33	Antiviral Agents (Antivirals)IBA 12/2023 - 01/2004
28	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
24	Hepatitis B e AntigensIBA 03/2014 - 01/2002
23	DNA (Deoxyribonucleic Acid)IBA 04/2022 - 02/2002
17	Hepatitis B Surface Antigens (HBsAg)FDA Link 10/2023 - 01/2002
15	Alanine Transaminase (SGPT)IBA 03/2016 - 01/2003
13	lenvatinibIBA 10/2023 - 01/2020
11	entecavir FDA Link 01/2022 - 06/2007
10	AntigensIBA 01/2022 - 01/2002
10	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022 - 01/2003
10	Amino Acids FDA Link 09/2015 - 08/2008
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 08/2008
7	BilirubinIBA 10/2017 - 01/2003
7	miriplatinIBA 06/2017 - 01/2011
7	telaprevirIBA 10/2014 - 01/2010
6	AlbuminsIBA 01/2019 - 01/2009
6	Serum AlbuminIBA 10/2017 - 10/2007
6	adefovir dipivoxil (Hepsera)FDA Link 06/2014 - 01/2004
6	Transaminases (Aminotransferases)IBA 03/2012 - 08/2004
6	Interferon-betaIBA 01/2011 - 01/2008
5	Fetal Proteins (Fetoprotein)IBA 04/2021 - 09/2013
5	lipoarabinomannan (LAM)IBA 05/2017 - 06/2008
5	adefovirIBA 06/2014 - 01/2004
5	Proteins (Proteins, Gene)FDA Link 02/2011 - 03/2006
5	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2011 - 01/2006
5	Interferon-alpha (Interferon Alfa)IBA 12/2010 - 02/2002
4	Hemoglobins (Hemoglobin)IBA 07/2023 - 11/2004
4	Cell-Free Nucleic AcidsIBA 01/2023 - 12/2020
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022 - 02/2002
4	NucleotidesIBA 02/2022 - 09/2004
4	Sodium-Glucose Transport ProteinsIBA 01/2022 - 01/2017
4	SofosbuvirIBA 01/2021 - 01/2017
4	Glucose (Dextrose)FDA LinkGeneric 02/2020 - 06/2012
4	asunaprevirIBA 09/2018 - 03/2016
4	daclatasvirIBA 09/2018 - 03/2016
4	Protease Inhibitors (Protease Inhibitor)IBA 01/2017 - 01/2010
4	Aspartic Acid (Aspartate)FDA Link 04/2010 - 05/2004
3	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2017
3	CanagliflozinIBA 01/2022 - 05/2019
3	Surface Antigens (Surface Antigen)IBA 01/2022 - 12/2002
3	TransferasesIBA 04/2021 - 08/2004
3	Tenofovir (Viread)FDA Link 04/2021 - 01/2014
3	NucleosidesIBA 05/2017 - 06/2007
3	CreatinineIBA 03/2014 - 03/2013
3	Dihydrotachysterol (AT 10)IBA 01/2014 - 03/2009
3	PlatinumIBA 03/2013 - 04/2009
3	Methionine (L-Methionine)FDA Link 04/2010 - 05/2004
3	Tyrosine (L-Tyrosine)FDA Link 04/2010 - 05/2004
2	GlycolipidsIBA 09/2023 - 11/2020
2	Bevacizumab (Avastin)FDA Link 09/2023 - 01/2022
2	atezolizumabIBA 09/2023 - 01/2022
2	Tumor Biomarkers (Tumor Markers)IBA 04/2022 - 01/2008
2	tenofovir alafenamideIBA 02/2022 - 11/2021
2	Circular DNAIBA 01/2022 - 01/2019
2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 08/2020

Therapy/Procedure

142	Therapeutics 10/2023 - 01/2002
15	Radiofrequency Ablation 02/2019 - 01/2002
7	Drug Therapy (Chemotherapy) 09/2023 - 11/2011
6	Drug Tapering 10/2013 - 07/2004
5	Aftercare (After-Treatment) 01/2022 - 12/2006
5	Retreatment 03/2019 - 04/2003
3	Hepatectomy 10/2020 - 11/2017
2	Precision Medicine 01/2023 - 04/2022
2	Plasma Exchange 10/2022 - 10/2004